Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Ask about realistic expectations
Overview of main clinical studies for MASLD/MASH with GLP-1 receptor agonists and dual or triple agonists targeting glucagon/GIP/GLP-1 receptors Liraglutide Liraglutide, a once-daily GLP-1 receptor agonist with authorized indications for type 2 diabetes and obesity, was evaluated in the LEAN trial (NCT01237119), a phase 2 randomized controlled study enrolling 52 adults with biopsy-proven MASH [22]
All of the compounds above have been proven to maintain GSH contents and GSH-dependent antioxidant enzyme activities in the myocardium, protecting it from oxidative stress [41, 158,159,160,161,162,163,164]
No unnecessary fillers
You might also notice cosmetic improvements in skin quality
